AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31656505 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B, n=25)
Number of subjects: 40
Study 29366703 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of bivalent HPV vaccine
Number of subjects: 0
Study 29366703 — intervention group
Group type: COMPARATOR
Intervention: Three doses of HPV vaccine
Number of subjects: 0
Study 26084406 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1 g/8 hours) plus Daptomycin (6 mg/kg/day)
Number of subjects: 32
Study 26084406 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2 g/8 hours)
Number of subjects: 32
Study 24390407 — intervention group
Group type: EXPERIMENTAL
Intervention: untargeted UPLC‐qTOF‐MS metabolomics analysis on urine samples
Number of subjects: 107
Study 24390407 — intervention group
Group type: COMPARATOR
Intervention: previous meal study
Number of subjects: 107
Study 23727737 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 40
Study 23727737 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide
Number of subjects: 40
Study 23727737 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g sodium perborate
Number of subjects: 40
Study 23727737 — intervention group
Group type: COMPARATOR
Intervention: Control (0.04 ml distilled water)
Number of subjects: 40
Study 23727737 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison among carbamide peroxide, sodium perborate, and hydrogen peroxide after two bleaching sessions (day 14)
Number of subjects: 40
Study 21995695 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin gastrointestinal therapeutic system (GITS) 4 mg
Number of subjects: 207
Study 21995695 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg
Number of subjects: 207
Study 18280222 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 16153674 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in grating detection in the amblyopic eye near pre‐training cut‐off spatial frequency
Number of subjects: 23
Study 16153674 — intervention group
Group type: EXPERIMENTAL
Intervention: Training regimen of repeated contrast‐sensitivity function measurements in the amblyopic eye
Number of subjects: 23
Study 16153674 — intervention group
Group type: COMPARATOR
Intervention: No training (Control Group III)
Number of subjects: 23
Study 14578408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine
Number of subjects: 24
Study 14578408 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide
Number of subjects: 24
Study 10973645 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-of-change oriented smoking cessation intervention
Number of subjects: 204
Study 10973645 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 204
Study 8788832 — intervention group
Group type: EXPERIMENTAL
Intervention: Discarding 1.5 ml of blood from the catheter
Number of subjects: 9
Study 1740940 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (G)
Number of subjects: 18
Study 1740940 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and lipid (GF)
Number of subjects: 18
Study 6131635 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (0.5 mg/kg/h for 2 h)
Number of subjects: 11
Study 30278263 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC) alone
Number of subjects: 40
Study 30278263 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Exercise (SE) alone
Number of subjects: 40
Study 30278263 — intervention group
Group type: EXPERIMENTAL
Intervention: RIC plus SE
Number of subjects: 40
Study 30278263 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 40
Study 30146935 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 5022
Study 30146935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5022
Study 26719915 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan/amlodipine
Number of subjects: 75
Study 26719915 — intervention group
Group type: COMPARATOR
Intervention: telmisartan/hydrochlorothiazide
Number of subjects: 75
Study 24792106 — intervention group
Group type: EXPERIMENTAL
Intervention: OZil Intelligent Phaco torsional mode (Group 1)
Number of subjects: 80
Study 24792106 — intervention group
Group type: COMPARATOR
Intervention: Combined torsional/longitudinal ultrasound mode (Group 2)
Number of subjects: 80
Study 24792106 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group 1 and Group 2
Number of subjects: 80
Study 22789884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 44
Study 22789884 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 10 mg once daily
Number of subjects: 44
Study 22789884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 44
Study 22789884 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 44
Study 21186969 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 20-70 mg/day
Number of subjects: 0
Study 18065591 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Number of subjects: 17046
Study 18065591 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17046
Study 16344401 — intervention group
Group type: EXPERIMENTAL
Intervention: PV isolation in combination with linear ablation joining the 2 superior PVs (roofline)
Number of subjects: 90
Study 16344401 — intervention group
Group type: COMPARATOR
Intervention: PV isolation alone
Number of subjects: 90
Study 12487686 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic submaximal trial (40.18 +/‐ 0.73% O(2); SUB(40))
Number of subjects: 25
Study 12487686 — intervention group
Group type: COMPARATOR
Intervention: Normoxic submaximal trial (20.93 +/‐ 0.22% O(2); SUB(21))
Number of subjects: 25
Study 9477394 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 34
Study 9477394 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 34
Study 9477394 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 7879931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal morphine (1 mg in 20 ml saline)
Number of subjects: 110
Study 7879931 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal saline and 1 mg intravenous morphine
Number of subjects: 110
Study 7879931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine (20 ml 0.25%)
Number of subjects: 110
Study 7879931 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural morphine (1.5 mg in 30 ml saline)
Number of subjects: 110
Study 7879931 — intervention group
Group type: COMPARATOR
Intervention: Interpleural saline and 1.5 mg intravenous morphine
Number of subjects: 110
Study 7879931 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural bupivacaine (30 ml 0.25%)
Number of subjects: 110
Study 2121204 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 0
Study 2121204 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide
Number of subjects: 0
Study 494997 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide bromide
Number of subjects: 10
Study 494997 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide chloride
Number of subjects: 10
Study 494997 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 30657891 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin alone or with candesartan and hydrochlorothiazide (HCT)
Number of subjects: 12705
Study 30657891 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rosuvastatin with candesartan/HCT
Number of subjects: 12705
Study 30657891 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and candesartan/HCT
Number of subjects: 12705
Study 30657891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheapest equivalent substitutes
Number of subjects: 12705
Study 27839957 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 120
Study 27839957 — intervention group
Group type: COMPARATOR
Intervention: PO acetaminophen
Number of subjects: 120
Study 26131808 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular access dysfunction
Number of subjects: 26133
Study 26131808 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular access dysfunction frequency (≥3 events)
Number of subjects: 26133
Study 26131808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vascular access dysfunction)
Number of subjects: 26133
Study 23246081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower resting ankle-brachial index (ABI)
Number of subjects: 22
Study 23246081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower resting ABI
Number of subjects: 22
Study 23246081 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced bilateral hip extensor strength
Number of subjects: 22
Study 21882799 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management (CM) plus usual nursing care
Number of subjects: 0
Study 21882799 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing care alone
Number of subjects: 0
Study 19207601 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 800 mg bid (Study 1)
Number of subjects: 0
Study 19207601 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg bid (Study 2)
Number of subjects: 0
Study 19207601 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg once a day
Number of subjects: 0
Study 17227264 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (500 IU) in normal saline (HS)
Number of subjects: 65
Study 17227264 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 65
Study 12699950 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde catheterisation of the aortic valve (n=101)
Number of subjects: 152
Study 12699950 — intervention group
Group type: COMPARATOR
Intervention: No passage through the aortic valve (n=51)
Number of subjects: 152
Study 12699950 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=32)
Number of subjects: 152
Study 10745070 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunelle Monthly Contraceptive Injection (MPA/E(2)C)
Number of subjects: 207
Study 10745070 — intervention group
Group type: COMPARATOR
Intervention: Ortho-Novum 7/7/7 (NET/EE)
Number of subjects: 207
Study 9193192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meta-chlorophenylpiperazine (mCPP) 0.1 mg/kg
Number of subjects: 16
Study 9193192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8262115 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 76
Study 8262115 — intervention group
Group type: COMPARATOR
Intervention: Luteinizing hormone-releasing hormone analogue depot preparation and flutamide
Number of subjects: 76
Study 3543785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Healon)
Number of subjects: 175
Study 3543785 — intervention group
Group type: COMPARATOR
Intervention: Balanced Saline Solution (BSS)
Number of subjects: 175
Study 30130990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application 'Karada‐no‐kimochi'
Number of subjects: 1526
Study 30130990 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention
Number of subjects: 1526
Study 26171678 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel Ag dressing
Number of subjects: 89
Study 26171678 — intervention group
Group type: COMPARATOR
Intervention: Acticoat dressing
Number of subjects: 89
Study 25198033 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrodebrider sinus irrigation (HSI)
Number of subjects: 12
Study 22744718 — intervention group
Group type: EXPERIMENTAL
Intervention: Short- and long-term antibiotic treatments
Number of subjects: 434
Study 20431220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 50
Study 20431220 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1.0%
Number of subjects: 50
Study 18986066 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial biological motion recognition task
Number of subjects: 54
Study 15583913 — intervention group
Group type: EXPERIMENTAL
Intervention: BMIPP imaging (normal uptake)
Number of subjects: 167
Study 15583913 — intervention group
Group type: EXPERIMENTAL
Intervention: sTL imaging (SDS <3 but impaired BMIPP uptake)
Number of subjects: 167
Study 15583913 — intervention group
Group type: EXPERIMENTAL
Intervention: sTL imaging (SDS <3)
Number of subjects: 167
Study 15583913 — intervention group
Group type: EXPERIMENTAL
Intervention: BMIPP imaging (reduced uptake)
Number of subjects: 167
Study 15583913 — intervention group
Group type: EXPERIMENTAL
Intervention: sTL imaging (SDS >=3)
Number of subjects: 167
Study 15583913 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 167
Study 15583913 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced ejection fraction
Number of subjects: 167
Study 11488118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate solution
Number of subjects: 638
Study 11488118 — intervention group
Group type: COMPARATOR
Intervention: Standard polyethylene glycol preparation
Number of subjects: 638
Study 9232521 — intervention group
Group type: EXPERIMENTAL
Intervention: RheothRx injection (poloxamer 188) administered as an intravenous infusion at doses of 10, 30, and 45 mg/kg/h for 72 h, 60 mg/kg/h for 43.3 to 72 h, 60 and 90 mg/kg/h for 24 h
Number of subjects: 36
Study 9232521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8121319 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil (600 mg per day for 21 days)
Number of subjects: 11
Study 8121319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3674301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-deprived condition (defined as less than 3 hours of sleep in a 24 hour period)
Number of subjects: 0
Study 3674301 — intervention group
Group type: COMPARATOR
Intervention: Nonsleep-deprived condition
Number of subjects: 0
Study 29914698 — intervention group
Group type: EXPERIMENTAL
Intervention: 25°C environment
Number of subjects: 28
Study 29914698 — intervention group
Group type: EXPERIMENTAL
Intervention: 35°C environment
Number of subjects: 28
Study 29914698 — intervention group
Group type: COMPARATOR
Intervention: 15°C environment
Number of subjects: 28
Study 27267983 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal educational intervention consisting of two online modules, a face-to-face workshop for GP trainees, a face-to-face workshop for their supervisors, and case-based discussions in weekly meetings.
Number of subjects: 0
Study 27267983 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-equivalent control group design)
Number of subjects: 0
Study 23521046 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Focused Brief Therapy (SFBT)
Number of subjects: 38
Study 23521046 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 38
Study 23845078 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin with usual care (n = 102)
Number of subjects: 204
Study 23845078 — intervention group
Group type: COMPARATOR
Intervention: Placebo with usual care (n = 102)
Number of subjects: 204
Study 21180396 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushes priced between 1 and 2 Euro (Category B)
Number of subjects: 140
Study 21180396 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushes priced at over 2 Euro (Category C)
Number of subjects: 140
Study 21180396 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushes priced under 1 Euro (Category A)
Number of subjects: 140
Study 18383539 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg plus MTX
Number of subjects: 0
Study 18383539 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg every 2 weeks plus MTX
Number of subjects: 0
Study 18383539 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 0
Study 16009466 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of testosterone
Number of subjects: 0
Study 16009466 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of estradiol
Number of subjects: 0
Study 16009466 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of SHBG
Number of subjects: 0
Study 16009466 — intervention group
Group type: COMPARATOR
Intervention: Lowest tertile of testosterone
Number of subjects: 0
Study 16009466 — intervention group
Group type: COMPARATOR
Intervention: Lowest tertile of estradiol
Number of subjects: 0
Study 16009466 — intervention group
Group type: COMPARATOR
Intervention: Lowest tertile of SHBG
Number of subjects: 0
Study 12580985 — intervention group
Group type: EXPERIMENTAL
Intervention: High enalaprilat concentration (above 50 ng ml(‐1), n = 17)
Number of subjects: 35
Study 12580985 — intervention group
Group type: EXPERIMENTAL
Intervention: Low enalaprilat concentration (below 10 ng ml(‐1), n = 18)
Number of subjects: 35
Study 11966062 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral prednisolone (30 mg if age < 5 years; 60 mg if age > 5 years)
Number of subjects: 259
Study 11966062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 8651631 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir-prednisone
Number of subjects: 99
Study 8651631 — intervention group
Group type: COMPARATOR
Intervention: Placebo-prednisone
Number of subjects: 99
Study 1460160 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week class and discussion group
Number of subjects: 0
Study 1460160 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-unit self-help manual
Number of subjects: 0
Study 1460160 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hr feedback and advice session with professional staff
Number of subjects: 0
Study 2983641 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen treatment
Number of subjects: 7
Study 2983641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29045621 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of proton pump inhibitors (PPIs)
Number of subjects: 16704
Study 29045621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative duration of PPIs use (per month)
Number of subjects: 16704
Study 29045621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dosage of PPIs use (per microgram)
Number of subjects: 16704
Study 26175036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser, NB‐UVB phototherapy, and 0.05% clobetasol propionate cream (Group A)
Number of subjects: 27
Study 26175036 — intervention group
Group type: COMPARATOR
Intervention: NB‐UVB phototherapy and 0.05% clobetasol propionate cream (Group B)
Number of subjects: 27
Study 24559757 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS)
Number of subjects: 10
Study 24559757 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (Control)
Number of subjects: 10
Study 21520391 — intervention group
Group type: EXPERIMENTAL
Intervention: Radpad radiation shield
Number of subjects: 60
Study 21520391 — intervention group
Group type: COMPARATOR
Intervention: No radiation shield protection
Number of subjects: 60
Study 21187536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) - 10 mg per kg body weight, administered intravenously 10 minutes prior to incision
Number of subjects: 42
Study 21187536 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TA)
Number of subjects: 42
Study 17982182 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading dose and 10 mg daily maintenance dose)
Number of subjects: 13608
Study 17982182 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading dose and 75 mg daily maintenance dose)
Number of subjects: 13608
Study 17982182 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 13608
Study 17982182 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13608
Study 15476575 — intervention group
Group type: COMPARATOR
Intervention: Calcium and cholecalciferol supplement (500 mg of elemental calcium and 400 IU cholecalciferol)
Number of subjects: 48
Study 15476575 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate (25 mg intramuscularly every month) in addition to calcium and cholecalciferol supplement
Number of subjects: 48
Study 11511426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac IL6 mRNA levels in patients with advanced heart failure
Number of subjects: 20
Study 11511426 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular IL6 mRNA levels
Number of subjects: 20
Study 11511426 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular IL6 mRNA levels
Number of subjects: 20
Study 11511426 — intervention group
Group type: EXPERIMENTAL
Intervention: IL6R expression
Number of subjects: 20
Study 11825486 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) with total parenteral nutrition (TPN) for 7 days
Number of subjects: 17
Study 11825486 — intervention group
Group type: COMPARATOR
Intervention: total parenteral nutrition (TPN) only for 7 days
Number of subjects: 17
Study 8164328 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) continuous infusion at a rate of 50 ng.kg‐1 x min‐1
Number of subjects: 12
Study 8164328 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 12
Study 8164328 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) continuous infusion
Number of subjects: 12
Study 8164328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 2450113 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical flunisolide (50 micrograms, each nostril, twice daily) for 1 week before antigen challenge
Number of subjects: 11
Study 2450113 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study 31351135 — intervention group
Group type: EXPERIMENTAL
Intervention: Onsite specimen processing
Number of subjects: 62
Study 31351135 — intervention group
Group type: COMPARATOR
Intervention: Offsite specimen processing
Number of subjects: 62
Study 30018101 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Clubs intervention (structured programme with 20 modules, facilitated groups, and home visits)
Number of subjects: 1008